Skip to main content

Advertisement

Table 1 Pretreatment characteristics of 184 patients with mid/low rectal cancer

From: Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial

Variable TME group (cases [%]) CCRT + TME group (cases [%]) χ 2 P
Total 94 90   
Sex    1.199 0.273
 Male 51 (54.3) 56 (62.2)   
 Female 43 (45.7) 34 (37.8)   
Distance from the lower tumor margin to the anal verge 1.119 0.290
 ≤5 cm 47 (50.0) 52 (57.8)   
>5-10 cm 47 (50.0) 38 (42.2)   
T stage    6.833 0.033
 cT2 8 (8.5) 2 (2.2)   
 cT3 69 (73.4) 60 (66.7)   
 cT4 17 (18.1) 28 (31.1)   
N stage    3.305 0.069
 cN0 48 (51.1) 33 (36.7)   
 cN+ 46 (48.9) 57 (63.3)   
Clinical stage    2.752 0.097
 II 48 (51.1) 33 (36.7)   
 III 46 (48.9) 57 (63.3)   
  1. TME, total mesorectal excision; CCRT, concurrent chemoradiotherapy